Gary Marshall Gary Marshall

Biossil Inc. in its US$43-million financing round

On April 21, 2026, Biossil Inc. announced its US$43-million financing round co-led by Founders Fund and OpenAI. The financing will be used to support the company’s mission of offering previously failed drugs a chance to advance to approval at a fraction of traditional cost and...

Lead Office: Toronto Date Announced: April 21, 2026 Value: US$43 million

FutureFit AI in its strategic investment from Achieve Partners

On April 13, 2026, FutureFit AI announced that it received a strategic investment from Achieve Partners to advance FutureFit AI’s mission of assisting more people navigate to better jobs at a faster and cheaper rate. FutureFit AI is workforce development technology platform. Osler, Hoskin...

Lead Office: Toronto Date Announced: April 13, 2026 Value: --

Roomiy Finance in its pre-seed financing round

On March 31, 2026, Roomiy Finance announced it had closed its pre-seed financing round. The round was led by Better Tomorrow Ventures, with participation from Slow Ventures and Endurance Ventures. This financing will allow Roomiy Finance to advance their vision to build fintech for hotel owner...

Lead Office: Toronto Date Announced: March 31, 2026 Value: --

Tailscale in its acquisition of Border0

On March 17, 2026, Tailscale announced that it acquired Border0. This acquisition will support Tailscale’s goal of building out its privileged access management capabilities. Tailscale is a Toronto-based software company that provides zero-configuration virtual private networks (VPNs) for...

Lead Office: Toronto Date Announced: March 17, 2026 Value: --

The SRTX Group (Sheertex) in its transaction implemented under the Bankruptcy and Insolvency Act

SRTX Inc. and its affiliates (collectively, the SRTX Group), widely known for their rip-resistant tights marketed under the Sheertex brand, operate in the textile and apparel industry. As a result of certain liquidity issues, the SRTX Group launched a strategic review in October 2025 with a view...

Lead Office: Montreal Date Closed: February 26, 2026 Value: --

Taalas in its raising of US$169 million

On February 19, 2026, Taalas announced that it raised $169 million and developed a chip capable of using artificial intelligence applications faster and more cost effectively than traditional approaches. Taalas is an artificial intelligence chip startup based in Toronto. Osler, Hoskin &...

Lead Office: Toronto Date Announced: February 19, 2026 Value: US$169 million

BioRender in Dimension Capital’s investment at a $900-million valuation

On December 18, 2025, BioRender announced that it facilitated a secondary purchase by Dimension Capital at a $900-million valuation. BioRender is a web-based platform that crafts and shares visually engaging scientific figures for communication and publication purposes. Osler, Hoskin &...

Lead Office: Toronto Date Announced: December 18, 2025 Value: $900 million

Genesys Capital in Enspire DBS Therapy’s $10.3-million Series B1 financing

On January 13, 2026,  Enspire DBS Therapy, Inc. announced that it raised $10.3 million in a Series B1 financing led by Genesys Capital. It also saw participation from existing investors Cleveland Clinic and JobsOhio Ventures. Genesys Capital invests in and builds companies in the...

Lead Office: Toronto Date Announced: January 13, 2026 Value: $10.3 million

Impression Ventures in 401GO’s $33-million Series B financing

On December 9, 2025, 401GO announced it raised $33 million of Series B Financing in a round that was led by Centana Growth Partners and had participation from Impression Ventures, Next Frontier Capital and Rally Ventures. Impression Ventures is a Toronto-based venture capital firm that invests...

Lead Office: Toronto Date Announced: December 9, 2025 Value: $33 million

AmacaThera in its licensing agreement with Pacira Biosciences for US$230 million

On November 4, 2025, AmacaThera announced that it signed an exclusive global licensing agreement with Pacira Biosciences for up to US$230 million, validating its tunable drug delivery platform. AmacaThera is a leading developer of next-generation hydrogel-based drug delivery solutions. Using a...

Lead Office: Toronto Date Announced: November 4, 2025 Value: US$230 million